Her2 treatment drugs

Several new drugs now have shown clinical evidence that they can be used to treat HER2-low BC as part of HER2-targeted therapy, reflecting the clearly unmet treatment needs of HER2-low BC. Researchers are exploring targeted therapies for HER2-low BC, but HER2 expression levels must be identified to guide treatment.

Anti-HER2 drugs for the treatment of advanced HER2 positive breast cancer. Stanowicka-Grada Malwina, Senkus Elżbieta. DOI wersji wydawcy

HER2 amplification-positive patients might benefit from existing HER2-targeted drugs, but some HER2 mutations result in resistance to the same treatments 6,11,12,13.

Drugs that specifically treat HER2 breast cancer are called anti-HER2 drugs. Designed to only attack the cancer cells, they include HER2 antibodies, HER2

Anti-HER2 therapy has revolutionized the treatment of HER2-positive breast cancer. However, HER2 has emerged as a driver of various other cancers and the indications for HER2-targeted therapy have

The treatment paradigm in HER2-positive advanced BC (ABC) has been increasingly transformed since the development of several additional HER2-targeted drugs. HER2-targeting represents the treatment cornerstone in this setting, including monoclonal antibodies, tyrosine kinase inhibitors and, recently, antibody drug conjugates (ADCs).

Anti-HER2 therapy has revolutionized the treatment of HER2-positive breast cancer. However, HER2 has emerged as a driver of various other cancers and the indications for HER2-targeted therapy have

The HER2-positive cancers tend to grow and spread faster than HER2-negative breast cancers but respond more effectively to treatment with drugs that target the

Margetuximab (Margenza ) in combination with chemotherapy was approved in 2024 for use in patients with metastatic HER2-positive breast cancer who have received prior treatments with other HER2-targeted therapies. Drugs to target HER2 were also developed for HER2-positive breast cancer treatment.